0 14 Identification identification NN 15 17 of of IN 18 19 a a DT 20 25 human human JJ 26 33 LIM-Hox LIM-Hox NNP 34 38 gene gene NN 38 39 , , , 40 45 hLH-2 hlh-2 NN 45 46 , , , 47 57 aberrantly aberrantly RB 58 67 expressed express VBN 68 70 in in IN 71 78 chronic chronic JJ 79 90 myelogenous myelogenous JJ 91 100 leukaemia leukaemia NN 101 104 and and CC 105 112 located locate VBN 113 115 on on IN 116 125 9q33-34.1 9q33-34.1 CD 125 126 . . . 128 130 We we PRP 131 139 describe describe VBP 140 143 the the DT 144 153 isolation isolation NN 154 156 of of IN 157 162 human human JJ 163 167 LH-2 lh-2 NN 167 168 , , , 169 170 a a DT 171 179 putative putative JJ 180 193 transcription transcription NN 194 200 factor factor NN 201 211 containing contain VBG 212 215 two two CD 216 229 cysteine-rich cysteine-rich JJ 230 237 regions region NNS 238 239 ( ( ( 239 242 LIM LIM NNP 243 250 domains domain NNS 250 251 ) ) ) 252 255 and and CC 256 257 a a DT 258 266 homeobox homeobox NN 267 268 ( ( ( 268 271 Hox Hox NNP 271 272 ) ) ) 273 284 DNA-binding dna-binding JJ 285 291 domain domain NN 291 292 . . . 293 297 High high JJ 298 304 levels level NNS 305 307 of of IN 308 313 hLH-2 hlh-2 NN 314 324 expression expression NN 325 329 were be VBD 330 338 observed observe VBN 339 341 in in IN 342 345 all all DT 346 351 cases case NNS 352 354 of of IN 355 362 chronic chronic JJ 363 374 myelogenous myelogenous JJ 375 384 leukaemia leukaemia NN 385 386 ( ( ( 386 389 CML CML NNP 389 390 ) ) ) 391 397 tested test VBN 397 398 , , , 399 409 regardless regardless RB 410 412 of of IN 413 420 disease disease NN 421 428 status. status. NN 429 434 hLH-2 hlh-2 NN 435 438 was be VBD 439 445 mapped map VBN 446 448 to to TO 449 459 chromosome chromosome NN 460 469 9Q33-34.1 9q33-34.1 NN 469 470 , , , 471 473 in in IN 474 477 the the DT 478 482 same same JJ 483 489 region region NN 490 492 as as IN 493 496 the the DT 497 507 reciprocal reciprocal JJ 508 521 translocation translocation NN 522 526 that that WDT 527 534 creates create VBZ 535 538 the the DT 539 546 BCR-ABL bcr-abl NN 547 554 chimera chimera NN 555 557 of of IN 558 561 the the DT 562 574 Philadelphia Philadelphia NNP 575 585 chromosome chromosome NN 586 587 ( ( ( 587 589 Ph Ph NNP 589 590 ’ ' '' 590 591 ) ) ) 591 592 , , , 593 596 the the DT 597 605 hallmark hallmark NN 606 608 of of IN 609 612 CML CML NNP 612 613 ; ; : 614 619 hLH-2 hlh-2 NN 620 623 was be VBD 624 632 retained retain VBN 633 635 on on IN 636 639 the the DT 640 650 derivative derivative JJ 651 652 9 9 CD 653 663 chromosome chromosome NN 664 667 and and CC 668 670 is be VBZ 671 680 therefore therefore RB 681 692 centromeric centromeric JJ 693 695 of of IN 696 701 c-ABL c-abl NN 701 702 . . . 703 706 The the DT 707 716 proximity proximity NN 717 719 of of IN 720 725 hLH-2 hlh-2 NN 726 728 to to TO 729 732 the the DT 733 743 breakpoint breakpoint NN 744 746 on on IN 747 757 chromosome chromosome NN 758 759 9 9 CD 760 766 raises raise VBZ 767 770 the the DT 771 782 possibility possibility NN 783 785 of of IN 786 800 cis-activation cis-activation NN 801 803 by by IN 804 807 the the DT 808 824 t(9;22)(q34;q11) t(9;22)(q34;q11) NN 825 838 translocation translocation NN 838 839 . . . 840 842 In in IN 843 851 addition addition NN 852 854 to to TO 855 862 finding find VBG 863 868 hLH-2 hlh-2 NN 869 879 expression expression NN 880 882 in in IN 883 886 all all DT 887 892 cases case NNS 893 895 of of IN 896 899 CML CML NNP 899 900 , , , 901 911 expression expression NN 912 915 was be VBD 916 924 observed observe VBN 925 927 in in IN 928 936 lymphoid lymphoid JJ 937 949 malignancies malignancy NNS 950 953 and and CC 954 961 myeloid myeloid JJ 962 966 cell cell NN 967 972 lines line NNS 972 973 , , , 974 977 but but CC 978 981 not not RB 982 984 in in IN 985 992 primary primary JJ 993 998 cases case NNS 999 1001 of of IN 1002 1007 acute acute JJ 1008 1019 myelogenous myelogenous JJ 1020 1029 leukaemia leukaemia NN 1029 1030 . . . 1031 1034 The the DT 1035 1039 role role NN 1040 1042 of of IN 1043 1048 hLH-2 hlh-2 NN 1049 1051 in in IN 1052 1055 the the DT 1056 1067 development development NN 1068 1070 or or CC 1071 1082 progression progression NN 1083 1085 of of IN 1086 1095 leukaemia leukaemia NN 1096 1098 is be VBZ 1099 1102 not not RB 1103 1108 known know VBN 1108 1109 . . . 1110 1117 However however RB 1117 1118 , , , 1119 1124 hLH-2 hlh-2 NN 1125 1128 may may MD 1129 1134 prove prove VB 1135 1141 useful useful JJ 1142 1144 as as IN 1145 1146 a a DT 1147 1153 marker marker NN 1154 1156 of of IN 1157 1160 CML CML NNP 1161 1164 for for IN 1165 1175 monitoring monitor VBG 1176 1184 residual residual JJ 1185 1192 disease disease NN 1192 1193 . . .